Gregory Szeto
Scientific Director - ADC Discovery and Immunology Pfizer
Greg is a Scientific Director in ADC Discovery at Pfizer with over 20 years of experience in immunology and oncology. He is trained as an immunologist, and systems and computational biologist. At Pfizer, Greg’s team focuses on discovering novel ADC payloads and evaluating ADC payload effects on tumor immunogenicity. Prior to Pfizer, Greg led teams at Seagen, the Allen Institute for Immunology, and the University of Maryland; he postdoc’d at MIT, and received his PhD from Johns Hopkins and BS from CMU.s
Seminars
Wednesday 10th June 2026
Defining How ADC Payloads Enhance Tumor Immunogenicity & Unlock Transformative Benefit With Immunotherapy
5:30 pm
- Examining clinical ADC combinations with immunotherapy
- Differentiating ADC payloads by tumor-intrinsic immunogenic cell death (ICD) and activity on immune cells
- Assessing evidence of vedotin ADC immunogenicity in patients
